Israel - heprea - Ministry of Health

pharmalogic ltd - methotrexate 10 mg/ml - solution for injection - methotrexate - antineoplastic chemotherapy: treatment of gestational choriocarcinoma, chorioadenoma destruents and hydatidiform mole. palliation of acute lymphocytic leukemia. in the treatment and prophylaxis of meningeal leukemia. greatest effect has been observed in palliation of acute lymphoblastic (stem cell) leukemias in children. in combination with other anticancer agents, methotrexate may be used for the induction of remission, but is most commonly used in maintenance of induced remissions. abitrexate may be used alone or in combination with other antineoplastics in the management of breast cancer, epidermoid cancers of the head and neck, lung cancer (particularly squamous cell and small cell types), bladder cancer and osteogenic cancer. methotrexate is effective in the treatment of the advanced stages (iii and iv peter's staging system) of lymphosarcoma, particularly in children, and in advanced cases of mycosis fungoides. psoriasis: because of the high risk attending its use, methotrexate is indicated only in the

Israel - heprea - Ministry of Health

pharmalogic ltd - oxytocin - תמיסה להזרקה\אינפוזיה - oxytocin 10 iu/ml - oxytocin - induction of labour for medical reasons stimulation of labour in hypotonic uterine inertia during caesarian section following the delivery ot the child prevention and treatment of postpartum uterine atony and haemorrhage.oxytocin injection may also be indicated in early stages of pregnancy as an adjunctive therapy for the management of incomplete inevitable or missed abortion.

Israel - heprea - Ministry of Health

pharmalogic ltd - gemcitabine as hydrochloride 200 mg - lyophilized powder for injection - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Israel - heprea - Ministry of Health

pharmalogic ltd - gemcitabine as hydrochloride 200 mg - lyophilized powder for injection - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Israel - heprea - Ministry of Health

pharmalogic ltd - gemcitabine as hydrochloride 1000 mg - lyophilized powder for injection - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Israel - heprea - Ministry of Health

pharmalogic ltd - gemcitabine as hydrochloride 1000 mg - lyophilized powder for injection - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Israel - heprea - Ministry of Health

pharmalogic ltd - gemcitabine as hydrochloride 10 mg - concentrate for solution for infusion - gemcitabine - palliative treatment of patients with locally advanced or metastatic non-small cell lung cancer and locally advanced or metastatic adenocarcinoma of the pancreas and for patients with 5-fu refractory pancreatic cancer. gemcitabine is indicated for the treatment of patients with bladder cancer at the invasive stage. breast cancer: gemcitabine in combination with paclitaxel is indicated for the treatment of patients with unresectable locally recurrent or metastatic breast cancer who have relapsed following adjuvant/neoadjuvant chemotherapy. prior chemotherapy should have included an anthracycline unless clinically contraindicated. ovarian cancer: gemcitabine in combination with carboplatin is indicated for the treatment of patients with recurrent epithelial ovarian carcinoma whom have relapsed at least six months after platinum - based therapy.

Israel - heprea - Ministry of Health

pharmalogic ltd - oxaliplatin 50 mg/vial - powder for concentrate for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil and folinic acid (fa) is indicated for : * adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour * treatment of advanced colorectal cancer.

Israel - heprea - Ministry of Health

pharmalogic ltd - oxaliplatin 100 mg/vial - powder for concentrate for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil and folinic acid (fa) is indicated for : * adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour * treatment of advanced colorectal cancer.

Israel - heprea - Ministry of Health

pharmalogic ltd - oxaliplatin 150 mg/vial - powder for concentrate for infusion - oxaliplatin - oxaliplatin in combination with 5- fluorouracil and folinic acid (fa) is indicated for : * adjuvant treatment of stage iii (duke's c) colon cancer after complete resection of the primary tumour * treatment of advanced colorectal cancer.